Balabanski L, Tashev T, Meretev A, Babulkov Kh
Vutr Boles. 1976 Dec;15(6):42-5.
The authors tested the tolerance and therapeutic effect of desopimon preparation (1-p-chlorophenyl-2-aminopropane hydrochloride) in 44 subjects with obesity--I, II and III degree. They found a manifested appetite-inhibiting effect of the medicament in 41 of the patients and slight in two (the treatment was discontinued in a female, due to urticaria). Side effects, similar to those described with phenformin and phenmethrazin derivatives were not established. Body-weight loss is 12,9 kg per subject for a period of a month and a half, and the analysis of the data revealed that the weight loss was entirely on the account of the fatty tissue reduction. Triglyceride diminution was established in serum whereas free fatty acids were increased. After the confrontation of their own data those of some other researchers, the authors recommend desopimon as a suitable additive means in the treatment of simple nutritive (hyperphagic) obesity.
作者对44例I、II和III度肥胖患者测试了去氧苯丙胺制剂（1-对氯苯基-2-氨基丙烷盐酸盐）的耐受性和治疗效果。他们发现，该药物在41例患者中表现出明显的食欲抑制作用，在2例患者中作用轻微（一名女性患者因荨麻疹而停药）。未发现与苯乙双胍和苯甲吗啉衍生物类似的副作用。在一个半月的时间里，每位受试者体重减轻12.9千克，数据分析表明，体重减轻完全是由于脂肪组织减少。血清甘油三酯降低，而游离脂肪酸增加。在将自己的数据与其他一些研究人员的数据进行对比后，作者推荐去氧苯丙胺作为治疗单纯营养性（多食性）肥胖的合适辅助手段。
